Special Issue

Honey Bee Products as an Alternative or Complement to Classical Antibiotics

Message from the Guest Editor

For some years now, we have been witnessing with concern the arrival of the post-antibiotic era. The resistance of pathogenic bacteria and fungi to well-known antibiotics and synthetic chemotherapeutics is becoming a major global health-care challenge. Therefore, there is a great need to find novel, non-antibiotic chemotherapeutics with marked antibacterial/antifungal activity. Bee products, including honey, propolis, royal jelly, pollen etc. constitute a promising but still underestimated group of potential antimicrobial chemotherapeutics. For centuries, bee honey and propolis comprised the most important raw materials of folk medicine. In contrast to many other popular traditional medicines, the achievements of modern medicine confirm the diverse therapeutic potential and synergistic interaction of bee products, which is a consequence of their chemical composition. Therefore, the main subject of this Issue is all aspects of the possible application of bee products (and the chemical ingredients in these products) for the treatment of bacterial or fungal infections. **Keywords: bacteria and fungi drug resistance; honey, propolis; pollen; bee products; polyphenols**

Guest Editor

Dr. Piotr Szweda

Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Gdansk, Poland

Deadline for manuscript submissions

closed (30 September 2020)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/39025

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI